Ocular allergy: update on clinical trials.

PURPOSE OF REVIEW The purpose of this article is to provide an update on the advances made through recent clinical trials regarding the treatment of the signs and symptoms of allergic conjunctivitis and its associated conditions. RECENT FINDINGS Recent studies have demonstrated significant advancement in the various forms of immunotherapy treatments. Nutritional interventions such as probiotics have surfaced as a viable complementary treatment option. Novel delivery methods such as contact lenses have been further studied along with a new tacrolimus formulation to improve ocular levels of the drug. SUMMARY Currently, the primary advances in treatment for allergic conjunctivitis has shifted from new ophthalmic agents to immunotherapy and improvement of drug delivery. This includes the classic subcutaneous and sublingual and the novel epicutaneous and intralymphatic immunotherapy delivery systems as well as an edible rice vaccine. New targets for treatment have spurred research into new antagonist drugs such as (OC000459), a prostaglandin D2 antagonist. The Marinosolv formulation using tacrolimus shows promise and may be considered for other ophthalmic agents in the future. Other nonpharmacological treatments such as stenting and mechanical barrier gel have demonstrated their usefulness in treating ocular symptoms.

[1]  E. Takamura,et al.  Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis , 2019, Current eye research.

[2]  L. Ziska,et al.  Associations between alteration in plant phenology and hay fever prevalence among US adults: Implication for changing climate , 2019, PloS one.

[3]  I. Wang,et al.  Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis , 2019, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  R. Mösges,et al.  Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season , 2019, The World Allergy Organization journal.

[5]  P. Joly,et al.  Tacrolimus ointment in the management of atopic keratoconjunctivitis. , 2019, Journal francais d'ophtalmologie.

[6]  L. Bielory,et al.  Emerging Therapeutics for Ocular Surface Disease , 2019, Current Allergy and Asthma Reports.

[7]  E. Meier,et al.  Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects , 2019, Clinical ophthalmology.

[8]  P. Georgopoulos,et al.  Development of a semi-mechanistic allergenic pollen emission model. , 2019, The Science of the total environment.

[9]  Takahiro Minami,et al.  In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses , 2019, PloS one.

[10]  S. Nakowitsch,et al.  Pharmacokinetics of topically applied tacrolimus dissolved in Marinosolv, a novel aqueous eye drop formulation , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  A. Murakami,et al.  Dietary ω-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S. Asilsoy,et al.  Efficacy of allergen-blocker mechanical barrier gel on symptoms and quality of life in patients with allergic rhinitis , 2018, European Archives of Oto-Rhino-Laryngology.

[13]  T. S. Tat Adherence to Subcutaneous Allergen Immunotherapy in Southeast Turkey: A Real-Life Study , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[14]  E. Meier,et al.  Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model , 2018, Clinical ophthalmology.

[15]  F. Cavarzeran,et al.  Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops , 2018, Ocular immunology and inflammation.

[16]  P. Demoly,et al.  An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France , 2018, Allergy, Asthma & Clinical Immunology.

[17]  D. Zadok,et al.  Mini-monoka stenting for patients with perennial allergic conjunctivitis , 2018, Orbit.

[18]  H. Nolte,et al.  The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. , 2018, Allergology international : official journal of the Japanese Society of Allergology.

[19]  E. Valovirta,et al.  Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis. , 2018, Clinical therapeutics.

[20]  R. Mösges,et al.  A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy , 2017, Allergy.

[21]  S. Choi,et al.  Intralymphatic Immunotherapy Alleviates Allergic Symptoms During Allergen Exposure in Daily Life , 2017, Allergy, asthma & immunology research.

[22]  L. Klimek,et al.  Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis , 2017, Allergy.

[23]  R. O’Hehir,et al.  Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis , 2017, The Journal of allergy and clinical immunology.

[24]  T. Sugahara,et al.  Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. , 2017, Investigative ophthalmology & visual science.

[25]  R. Van Ree,et al.  Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation , 2017, International Archives of Allergy and Immunology.

[26]  M. Christman,et al.  Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial. , 2017, The American journal of clinical nutrition.

[27]  R. Kumari,et al.  Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis. , 2017, Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH.

[28]  A. Concheiro,et al.  Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. , 2016, Acta biomaterialia.

[29]  W. Carr,et al.  Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief , 2016, Allergy & rhinology.

[30]  Anita K. Bakrania,et al.  Combination treatment for allergic conjunctivitis - Plant derived histidine decarboxylase inhibitor and H1 antihistaminic drug. , 2015, Experimental eye research.

[31]  T. Kündig,et al.  Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials , 2015, Allergy.

[32]  R. Jacobs,et al.  Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  K. Fukuda,et al.  Prevention of allergic conjunctivitis in mice by a rice-based edible vaccine containing modified Japanese cedar pollen allergens , 2015, British Journal of Ophthalmology.

[34]  M. Blaiss,et al.  Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. , 2014, Allergy and asthma proceedings.

[35]  J. Wolffsohn,et al.  Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. , 2014, Ophthalmology.

[36]  L. Bielory,et al.  Emerging therapies in allergic conjunctivitis and dry eye syndrome , 2013, Expert opinion on pharmacotherapy.

[37]  F. Horak,et al.  The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial , 2012, Allergy.